Bortezomib
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
| - | <StructureSection load='' size='340' side='right' caption='Caption for this structure' scene=''> | + | <StructureSection load='' size='340' side='right' caption='Caption for this structure' scene='10/1022872/Cv/1'> |
Bortezomib, sold under the brand name Velcade among others, is an anti-cancer medication used to treat multiple myeloma and mantle cell lymphoma.<ref name="a2">[https://www.drugs.com/monograph/bortezomib.html "Bortezomib Monograph for Professionals".] Drugs.com. Retrieved 13 October 2019.</ref> This includes multiple myeloma in those who have and have not previously received treatment. It is generally used together with other medications.<ref name="a3">[https://www.ema.europa.eu/en/medicines/human/EPAR/velcade "Velcade".] European Medicines Agency (EMA). 17 September 2018. Retrieved 13 October 2019.</ref> | Bortezomib, sold under the brand name Velcade among others, is an anti-cancer medication used to treat multiple myeloma and mantle cell lymphoma.<ref name="a2">[https://www.drugs.com/monograph/bortezomib.html "Bortezomib Monograph for Professionals".] Drugs.com. Retrieved 13 October 2019.</ref> This includes multiple myeloma in those who have and have not previously received treatment. It is generally used together with other medications.<ref name="a3">[https://www.ema.europa.eu/en/medicines/human/EPAR/velcade "Velcade".] European Medicines Agency (EMA). 17 September 2018. Retrieved 13 October 2019.</ref> | ||
Revision as of 12:55, 15 January 2024
| |||||||||||
References
- ↑ "Bortezomib Monograph for Professionals". Drugs.com. Retrieved 13 October 2019.
- ↑ "Velcade". European Medicines Agency (EMA). 17 September 2018. Retrieved 13 October 2019.
